Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab and Anakinra with PD-1/PD-L1 Blockade in Relapsed/Refractory Metastatic NSCLC
NCT05013450Phase 2Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab, anakinra in non-small cell lung cancer (NSCLC). Started Sep 2021; status: active, not recruiting.
02
Drugs
dupilumabanakinra
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05013450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013450.